Teva Pharmaceutical Industries Ltd. has launched capecitabine tablets, a cancer medication, in 150-mg and 500-mg dosages in the United States.


Teva Pharmaceutical Industries, capecitabine tablets, generic equivalent to Xeloda, Genentech, cancer medication
































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Teva releases generic Xeloda tablets

March 7th, 2014

JERUSALEM – Teva Pharmaceutical Industries Ltd. has launched capecitabine tablets, a cancer medication, in 150-mg and 500-mg dosages in the United States.

Teva said Friday that its product is a generic equivalent to Xeloda (150 mg and 500 mg), marketed by Genentech in the United States.

Tevan noted that it was the first to receive approval on its Abbreviated New Drug Application (ANDA) from the Food and Drug Administration and is now rolling out the product according to a settlement agreement.

Xeloda tablets had annual U.S. sales of about $754 million as of December 2013, according to IMS Health figures reported by Teva.

Advertisement